Irisflorentin suppresses allergic inflammation in mast cells via reducing histamine release and production of pro-inflammatory cytokines

Allergic diseases afflict many people worldwide. Allergic inflammation encompassing acute allergic reaction and chronic inflammatory response is the major pathogenesis. To discovery novel therapeutic approach for allergic diseases, we have evaluated the anti-allergic inflammatory effects of irisflorentin using RBL-2H3 cells. The results showed certain concentrations of irisflorentin could suppress histamine release and secretion of TNF-α, IL-1β and IL-6. Further investigations indicated that the effects of irisflorentin were associated with a reduction of intracellular calcium, suppression of NF-κB signaling pathway and inhibition of caspase-1 activity. Therefore, the results of the current study demonstrated that irisflorentin can ameliorate mast cell-mediated allergic inflammation. These results can provide evidences for the discovery of novel therapy for allergic diseases and application of irisflorentin in practice.